[{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"SciClone Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ SciClone Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ SciClone Pharmaceuticals"},{"orgOrder":0,"company":"Radius Health","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Menarini","sponsor":"European Organisation for Research and Treatment of Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ European Organisation for Research and Treatment of Cancer","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ European Organisation for Research and Treatment of Cancer"},{"orgOrder":0,"company":"Onco360","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Onco360","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Onco360 \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Onco360 \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eisai","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eisai \/ DRI Healthcare Trust","highestDevelopmentStatusID":"15","companyTruncated":"Eisai \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Inapplicable"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Menarini","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Menarini","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Menarini \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"Menarini \/ Radius Health"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"15","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"European Organisation for Research and Treatment of Cancer","sponsor":"Breast International Group | Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"European Organisation for Research and Treatment of Cancer","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"European Organisation for Research and Treatment of Cancer \/ Breast International Group | Menarini","highestDevelopmentStatusID":"10","companyTruncated":"European Organisation for Research and Treatment of Cancer \/ Breast International Group | Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase III","graph3":"Radius Health","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Oral","sponsorNew":"Radius Health \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Menarini"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SOLTI Breast Cancer Research Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"SOLTI Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SOLTI Breast Cancer Research Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOLTI Breast Cancer Research Group \/ Inapplicable"},{"orgOrder":0,"company":"Yale University","sponsor":"Johns Hopkins University | Stemline Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Yale University \/ Johns Hopkins University | Stemline Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Johns Hopkins University | Stemline Therapeutics"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Context Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Context Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Context Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Context Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SOLTI Breast Cancer Research Group","sponsor":"Radius Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"SOLTI Breast Cancer Research Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"SOLTI Breast Cancer Research Group \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"SOLTI Breast Cancer Research Group \/ Radius Health"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stemline Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elacestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Approved FDF","graph3":"Stemline Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemline Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Stemline Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evexta Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rupitasertib","moa":"||HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Evexta Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evexta Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Evexta Bio \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Elacestrant

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 22, 2025

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Yale University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Yale University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 11, 2025

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Johns Hopkins University | Stemline Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 09, 2024

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Rupitasertib is an oral inhibitor of S6K and AKT1/AKT3 designed to block the PI3K/AKT/mTOR pathway, being investigated with elacestrant in ER+/HER2- advanced breast cancer with ESR1 mutation.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 22, 2024

                          Lead Product(s) : Rupitasertib,Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 19, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : European Organisation for Research and Treatment of Cancer

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)‑positive, HER2-negative, locally advanced or metastatic br...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 20, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the agreement, DRI Healthcare gains a portion of Radius’s royalty and commercial milestone stream in Orserdu (elacestrant), a selective estrogen receptor degrader and the first and only treatment approved for ER+/HER2-, ESR1- mutated advanced or ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : $130.0 million

                          August 14, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : DRI Healthcare Trust

                          Deal Size : $140.0 million

                          Deal Type : Agreement

                          blank

                          08

                          SOLTI Breast Cancer Research Group

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          SOLTI Breast Cancer Research Group

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 08, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Orserdu (elacestrant), an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERα), is indicated for the treatment of postmenopausal women, and men, with ER‑positive, HER2-negative, locally advanced or metastatic breast cancer with an ...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 21, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Under the agreement, SciClone will pursue the development and registration of Orserdu (elacestrant), a once-daily oral endocrine monotherapy, for the treatment of postmenopausal women or adult men, in China and commercialize Orserdu upon its regulatory a...

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 11, 2023

                          Lead Product(s) : Elacestrant

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : SciClone Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank